Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-03-03

Clinical Trial Update: Study of ARQ 197 in Hepatocellular Carcinoma (HCC) [Phase 1]

View source ↗

Summary

A Phase 1 trial of ARQ 197 for advanced hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ARQ 197 (tivantinib)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Advanced Hepatocellular Carcinoma | Phase 1 | Status: COMPLETED